Down 25% in a month, the Incannex share price is now halted. Here's why

A key update awaits the market from Incannex.

| More on:
A dollar sign embedded in ice, indicating a share price freeze or trading halt

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Incannex Healthcare shares are on the backburner today pending a company announcement 
  • Prior to the halt they were resting at 38 cents apiece. The company intends to release readouts from a recent clinical trial 
  • In the last 12 months, the Incannex Healthcare share price has held a 24% gain 

Shares of Incannex Healthcare Ltd (ASX: IHL) are on ice today pending a company announcement. Before being placed on the backburner, the Incannex share price rested at 38 cents apiece.

Zooming out, shares of the cannabis player have faltered more than 39% this year to date, amid a violent selloff in growth-type shares in 2022.

In wider market moves, the S&P/ASX 200 Health Care Index (ASX: XHJ) has crumbled today and is now more than 3% in the red, bringing losses to 12% this year.

Meanwhile, in the US, the Nasdaq Composite Index (Nasdaq) fell sharply overnight, marking its largest single-day drop since 2020.

Investors sold off shares in the tech-biased Nasdaq after US Federal Reserve chair Jerome Powell raised the Fed's base interest rate by 0.5 percentage points, in an effort to control inflationary pressures.

Why is the Incannex share price halted?

The company requested its shares be put on ice in lieu of a market-sensitive announcement regarding upcoming study readouts.

"[Incannex] requests a trading halt to be applied to its securities…pending an announcement by the company regarding results of its extensive preclinical study assessing IHL-216A in a sports concussion model," it said in the filing.

"The Company requests that the trading halt remains in place until the earlier of the commencement of normal trading on May 10, 2022 or the release of the announcement."

Naturally the ASX awarded Incannex its request and, as such, investors must now wait until the company posts its next update on or before May 10.

Earlier in the year, investors appeared rattled by Incannex's decision to acquire APIRx Pharmaceutical USA, LLC for US$93 million.

Even though it now claims a total addressable market of more than US$400 billion globally, investors didn't appear as thrilled.

As such, losses have continued into May and shares have stooped from a high of 70 cents in March.

Incannex Healthcare share price snapshot

In the last 12 months, the Incannex Healthcare share price has held a 24% gain. However, it has collapsed into the red on each of the shorter time frames.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
Healthcare Shares

Why are Mesoblast shares jumping 10% to a 52-week high?

This biotech is hitting new highs on Friday. Let's find out why.

Read more »

a group of surgeons in full surgery dress including masks, gloves and head coverings stands together with arms folded and smiling eyes as if happy with the outcome of their efforts.
Healthcare Shares

Ansell shares tumble to a 3-month low. Is this a buying opportunity?

Ansell shares have slid to a 3-month low. Could oversold signals point to a buying opportunity for long-term investors?

Read more »

Female scientist working in a laboratory.
Healthcare Shares

These three biotechs show how the sector can produce huge outsized gains, but are they still good value?

These drug developers' shares are trading near 12-month highs.

Read more »

A medical specialist holds a red heart connected via technology and artificial intelligence.
Healthcare Shares

This biotech is approaching 20-bagger status within a year and the good news continues to come

This company has just won approval to go ahead with a key clinical trial.

Read more »

An investor sits at a table in front of her laptop with a party hat on her head and a cake next to her symbolising new year's eve but the 4DS Memory share price is plunging so she looks very disappointed and depressed
Healthcare Shares

$5 billion ASX 200 healthcare stock tumbling on CEO exit

Investors are bidding down the ASX 200 healthcare giant on Thursday. Let’s see why.

Read more »

woman testing substance in laboratory dish, csl share price
Share Market News

After a 73% surge this ASX healthcare share looks far from done

Brokers are upbeat, and some see possible gains of 90% in 2026.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Which biotech's shares are surging higher on US patent news?

Investors like what they see from this drug company.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This biotech company's shares are on a tear – again – after another contract win

A new contract with a prestigious US institution spells good news for shareholders.

Read more »